Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন*
Indications:
METAVAS MR 35 mg is indicated for the treatment of:
-
Stable angina pectoris (chest pain due to heart disease)
-
As an add-on therapy in patients not adequately controlled by or intolerant to other anti-anginal agents
Pharmacology:
Trimetazidine is a metabolic agent that maintains cellular energy metabolism in ischemic conditions. It improves myocardial glucose utilization through inhibition of fatty acid metabolism. This leads to increased efficiency of ATP production in heart cells, thus protecting the heart from ischemia-induced damage and reducing angina symptoms.
Dosage & Administration:
The recommended dose is 35 mg twice daily (morning and evening) with meals.
Do not exceed the prescribed dose. Not intended for acute angina attacks.
Interaction:
Generally well tolerated with minimal drug interactions. No significant interactions with beta-blockers, calcium channel blockers, nitrates, or ACE inhibitors.
Contraindications:
-
Hypersensitivity to Trimetazidine or any component of the product
-
Patients with Parkinson’s disease, movement disorders, severe renal impairment (creatinine clearance <30 mL/min)
Side Effects:
Common: Dizziness, headache, abdominal pain, nausea, vomiting
Rare: Parkinsonian symptoms, tremors, gait disturbance, rash
Pregnancy & Lactation:
Not recommended during pregnancy or breastfeeding due to insufficient safety data. Use only if clearly needed and prescribed.
Precautions & Warnings:
-
Not suitable for use as first-line therapy or for acute angina attacks
-
Use caution in elderly patients and those with movement disorders
-
Discontinue if Parkinsonian symptoms appear
Therapeutic Class:
Anti-anginal metabolic agents (Cardiac metabolic therapy)
Storage Conditions:
Store in a cool, dry place below 30°C. Protect from moisture and sunlight. Keep out of the reach of children.
Change Language